Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Cyclosporine pharmacokinetics and effect in the Type I diabetic rat model

Summary

Recent clinical studies have demonstrated the potential benefit of the T-cell-specific immunosuppressant, cyclosporine, in the treatment of Type I insulin-dependent diabetes. In the present study, steady-state cyclosporine pharmacokinetics, fasting glucose and insulin levels and renal function were examined in stable insulin-dependent diabetic rats and compared to non-diabetic rats. Mean creatinine clearance 30 days following diabetes induction was not significantly different from saline controls. Cyclosporine treatment (5 mg/kg/day i.v. for 13 days) did not significantly alter creatinine clearance in either group; however, renal function of vehicle-treated diabetic rats was markedly reduced compared to other groups. Serum insulin concentrations were significantly greater in diabetic rats treated with cyclosporine compared to the control group (35.1±22.7 vs. 16.0±8.1 μU/ml;P<0.05). Glucose levels were proportionately reduced in diabetic rats treated with cyclosporine. Area under the concentration-time curve, half-life and volume of distribution of cyclosporine were significantly reduced in diabetic rats compared to non-diabetic controls. In summary, the pharmacokinetics and pharmacodynamics of cyclosporine were significantly different in the insulin-dependent diabetic rat model compared to normal controls. Furthermore, short-term cyclosporine therapy reduced the extent of experimental diabetic nephropathy observed in this model.

This is a preview of subscription content, log in to check access.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

References

  1. 1.

    Peins A.N., Gustafson A.B. (1986): Current therapeutic concepts in diabetic hypertension. Diabetes Care, 9, 409–414.

  2. 2.

    Diaz-Buxo J.A. (1986): Managing the diabetic with renal insufficiency. Int. J. Artif. Organs, 9, 207–212.

  3. 3.

    Eisenbarth G.S. (1986): Type I diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med., 314, 1360–1368.

  4. 4.

    Stiller C.R., Dupre J., Gent M., et al. (1984): Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science, 223, 1362–1367.

  5. 5.

    Assan R., Feutref G., Sirmai J. (1988): Cyclosporine trials in diabètes: Update results of the French experience. Transplant. Proc., 20, 178–183.

  6. 6.

    Stiller C.R., Dupre J., Gent M., et al. (1987): Effects of cyclosporine in recent-onset juvenile type I diabetes: Impact of age and duration of disease. J. Pediatr., 111, 1069–1072.

  7. 7.

    Bach J. (1987): Cyclosporine in insulin-dependent diabetes mellitus. J. Pediatr., 111, 1073–1074.

  8. 8.

    Matzke G.R., Luke D.R. (1988): Dialysis and renal transplant therapy. In: Herfindal E.T., Gourley D.R., Hart L.X. eds. Clinical Pharmacy and Therapeutics. Baltimore, Williams and Wilkins, pp. 229–242.

  9. 9.

    Assan R., Feytren G., Debray-Sachs M., et al. (1985): Metabolic and immunological effects in recently diagnosed type I diabetes mellitus. Lancet, 1, 67–71.

  10. 10.

    Brayman K.L., Armstrong J., Shaw L.M., et al. (1987): Prevention of diabetes in BB rats by intermittent administration of cyclosporine. Surgery, 102, 235–241.

  11. 11.

    Formby B., Miller N., Garret R., Peterson C.M. (1987): Effects of low dose cyclosporine prophylaxis in nonobese diabetic mice. J. Pharmacol. Exp. Ther., 241, 1106–1111.

  12. 12.

    Mahon J.L., Gunn H.C., Stobie K., et al. (1988): The effect of bromocryptine and cyclosporine on spontaneous diabetes in BB rats. Transplant. Proc., 20, 197–200.

  13. 13.

    Eun H., Pak C., Kim C., McArthur R.G., Yoon J. (1987): Role of cyclosporin A in macromolecular synthesis of beta-cells. Diabetes, 36, 952–958.

  14. 14.

    Hahn H.J., Kauert C., Kotzke G. (1987): Induction of a diabetes-like syndrome by cyclosporine in Wistar rats and its reversibility after drug withdrawal. Exp. Clin. Endocrinol., 90, 46–50.

  15. 15.

    Nielson J.H., Mandrup-Poulsen T., Nerup J. (1986): Direct effects of cyclosporin A on human pancreatic beta-cells. Diabetes, 35, 1049–1052.

  16. 16.

    Robertson R.P. (1986): Cyclosporine-induced inhibition of insulin secretion in isolated rat islets and HIT cells. Diabetes, 35, 1016–1019.

  17. 17.

    Sai P., Maugendre D., Loreal O., Maurel G., Pogu S. (1987): Effects of cyclosporine on autoimmune diabetes induced in — mice by streptozotocin: Beta cell-toxicity and rebound insulitis after cessation of treatment Diab. Metab., 14, 455–462.

  18. 18.

    von Schlifgaarde R., Burg M.P.M., Suylichem P.T.R., Frolich M., Gooszen H.G., Moolenaar A.J. (1987): Interference by cyclosporine with the endocrine function of the canine pancreas. Transplantation, 44, 13–16.

  19. 19.

    Zysset T., Weitholtz H. (1988): Differential effect of type I and type II diabetes on antipyrine disposition in man. Eur. J. Clin. Pharmacol., 34, 369–375.

  20. 20.

    D’Souza M.J., Solomon H.M., Fowler L.C., Pollock S.H. (1988): Pharmacokinetics of cyclosporine in streptozotocin-induced diabetic rats. Drug Metab. Dispos., 16, 778–780.

  21. 21.

    McNamara P.J., Blouin R.A., Brazzell R.K. (1988): The protein binding of phenytoin, propranolol, diazepam and AL01567 (an aldose reductase inhibitor) in human and rat diabetic serum. Pharm. Res., 5, 261–265.

  22. 22.

    de Souza C.J., Meier A.H. (1987): Orcadian and seasonal variations of plasma insulin and cortisotisol concentrations in the Syrian hamster,mesocricetus auratus. Chronobiol. Int, 4, 141–151.

  23. 23.

    Luke D.R., Vadiei K., Brunner L.J. (1988): Time-dependent pharmacokinetics and toxicity of cyclosporine. Chronobiol. Int, 240, 353–362.

  24. 24.

    Gibaldi M., Perrier D. (1982): Noncompartmental analysis based on statistical moment theory. In: Swarbrick J. ed. Pharmacokinetics. New York, Marcel Dekker, pp. 409–416.

  25. 25.

    Tompkins G.T., Brunner L.J., Luke D.A. (1989): Cilastatin-insulin interaction in the rat. Drug Metab. Dispos., 17, 54–57.

  26. 26.

    Mitch W.E. (1983): Nutrition in renal disease. In: Handbook of Renal Therapeutics, Martinez-Maidonado M. ed. New York, New York Plenum Medical Book Company, p. 360.

  27. 27.

    Attallah A.M., Abdelghaffar H., Fawzy A., et al. (1987): Cell-mediated immunity and biological response modifiers in insulin-dependent diabetes mellitus complicated by end-stage renal disease. Int Arch. Allergy Appl. Immun., 83, 278–283.

  28. 28.

    Tanaka E., Ishikawa A., Misawa S., Kuroiwa Y. (1988): Sex-related differences in hepatic drug-oxidizing capacity of streptozotocin-induced diabetc rats. J. Pharmacobio-Dyn., 11, 416–423.

  29. 29.

    Mahachai V., Hutchison S., Keelan M., Thompson A.B.R. (1988): In vivo hepatic microsomal function in diabetic rats. Clin. Pharmacol. Ther., 43, 174.

  30. 30.

    Emudianughe T.S., Kalderon B., Gopher A., Lapidot A. (1988): Effects of streptozotocin-induced diabetes on drug metabolism in rats. Arch. Int Pharmacodyn., 293, 14–19.

  31. 31.

    Ackerman D.M., Leibman K.C. (1977): Effect of experimental diabetes on drug metabolism in the rat Drug. Metab. Dispos., 5, 405–410.

Download references

Author information

Correspondence to D. R. Luke.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Brunner, L.J., Iyer, L.V., Vadiei, K. et al. Cyclosporine pharmacokinetics and effect in the Type I diabetic rat model. Eur. J. Drug Metab. Pharmacokinet. 14, 287–292 (1989). https://doi.org/10.1007/BF03190113

Download citation

Keywords

  • Cyclosporine
  • pharmacokinetics
  • diabetes
  • nephrotoxicity
  • insulin